





चित्र है				Q	01	14COICHIC		
PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMM	Books
Search PubMe	ed 🔠	for				Go Clear		
		Limits	Preview/Index History		ory	Clipboard	Details	
About Entrez	. 7							
	3792344	1000 TATAN	9 - 2 - 2 - 2	, _[01084-74/4 	79.57
Text Version	Dis	play Abstra	act <u>×</u>	Show: 20	Sort	Sen	d to Text	
Entrez PubMed	Γ1	: Trends Neu	ırosci. 2003 Jun	;26(6):297-3	302.		Related Arti	cles, Link
Overview Help FAQ		Protectiv	ve autoimmu	nity agair	nst the e	nemy withi	n• fiohtii	nσ
Tutorial		Protective autoimmunity against the enemy within: fighting glutamate toxicity.						
New/Noteworthy E-Utilities		giutama	ie toxicity.					
PubMed Services	es	Schwartz 1	M, Shaked I, F	isher J, Miz	zrahi T, So	chori H.		
Journals Database MeSH Database	•	Department of Neurobiology, The Weizmann Institute of Science, 76100,						
Single Citation Mat		Rehovot, Israel						
Batch Citation Mate Clinical Queries	cher	Remover, 1	Sido:					
LinkOut		Glutamate,	a key neurotran	smitter, is p	ivotal to C	NS function.	Alterations	in its
Cubby			on can be dange					
Related Resource	ces		ırodegenerative					
Order Documents		attributed to the efficient removal of glutamate from the extracellular milieu by						
NLM Gateway TOXNET		reuptake via local transport mechanisms. Our recent studies suggest that glutamate, either directly or indirectly, elicits a purposeful systemic						
Consumer Health	~							antigens
Clinical Alerts ClinicalTrials.gov		T-cell-mediated immune response directed against immunodominant self-antigens that reside at the site of glutamate-induced damage. We suggest that the harnessed						
PubMed Central		autoimmunity (which we have termed 'protective autoimmunity') helps the						
Privacy Policy		resident mi	croglia in their o	lual function	n as antige	n-presenting c	ells (servin	g the
			stem) and as cell					
			erving the nervo					
		adaptive immune response illustrates the bidirectional dialog between the immune						
		and nervous systems, under both physiological and pathological conditions. These results point to the possible development of a therapeutic vaccination with						
		self-antigens, or with antigens cross-reactive with self-antigens, as a way to						
		augment autoimmunity without inducing an autoimmune disease, thus providing a						
		safe method of limiting degeneration. This approach, which boosts a physiological						
		mechanism for the regulation of glutamate, and possibly also that of other						
		self-compounds, might prove to be a feasible strategy for therapeutic protection						

against glutamate-associated neurodegenerative or mental disorders.

: Show: 20

Sort

PMID: 12798598 [PubMed - in process]

Abstract

Send to Text